Aditya Jandial
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aditya Jandial has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Kundan Mishra
Commando Hospital, Lucknow, India
31 shared publications Gaurav Prakash
Department of Clinical Hematology and Medical Oncology Postgraduate Institute of Medical Education and Research Chandigarh India
29 shared publicationsAlka Khadwal
27 shared publications- Deepesh Lad
Post Graduate Institute of Medical Education and Research, Chandigarh, India
23 shared publications Pankaj Malhotra
23 shared publications- Pankaj Malhotra
Department of Clinical Hematology and Medical Oncology Postgraduate Institute of Medical Education and Research Chandigarh India
21 shared publications
Latest Publications
- 22 June 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (4) , e70215
Efficacy and Safety of Novel‐Agent–Based Front‐Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta‐Analysis
Older patients with classical Hodgkin lymphoma (cHL) have poorer outcomes than younger patients, largely due to comorbidities, reduced chemotherapy tolerance, and limited representation in clinical trials. Brentuximab Vedotin (BV) and PD‐1 inhibitors have entered frontline use in this population, but the optimal approach remains uncertain. We performed a systematic review and pooled analysis to evaluate the efficacy and safety of frontline regimens in patients aged ≥ 60 years with cHL. Studies reporting complete response (CR), overall response rate (ORR), progression‐free survival (PFS), and toxicity were included. Outcomes were pooled using random‐effects models. A total of 11 studies including 568 patients were analyzed. The pooled CR rate was 71% (95% CI: 57–81) and pooled 2‐year PFS was 66% (95% CI: 45–83), with significant heterogeneity. Nivolumab‐based regimens appeared, in indirect subgroup comparisons with marked heterogeneity, to have a higher pooled response rates and PFS than BV‐based regimens, and were associated with lower rates of treatment discontinuation, Grade ≥ 3 infections, and neuropathy. Novel agent‐based regimens produced better efficacy and lower toxicity than traditional chemotherapy in newly diagnosed older adults with cHL. Among novel agents, nivolumab‐based regimens had more favorable efficacy and tolerability than BV‐based regimens, though these comparisons are indirect and may reflect differences in study design and patient selection.
- 22 June 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (4) , e70215
Efficacy and Safety of Novel‐Agent–Based Front‐Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta‐Analysis
Older patients with classical Hodgkin lymphoma (cHL) have poorer outcomes than younger patients, largely due to comorbidities, reduced chemotherapy tolerance, and limited representation in clinical trials. Brentuximab Vedotin (BV) and PD‐1 inhibitors have entered frontline use in this population, but the optimal approach remains uncertain. We performed a systematic review and pooled analysis to evaluate the efficacy and safety of frontline regimens in patients aged ≥ 60 years with cHL. Studies reporting complete response (CR), overall response rate (ORR), progression‐free survival (PFS), and toxicity were included. Outcomes were pooled using random‐effects models. A total of 11 studies including 568 patients were analyzed. The pooled CR rate was 71% (95% CI: 57–81) and pooled 2‐year PFS was 66% (95% CI: 45–83), with significant heterogeneity. Nivolumab‐based regimens appeared, in indirect subgroup comparisons with marked heterogeneity, to have a higher pooled response rates and PFS than BV‐based regimens, and were associated with lower rates of treatment discontinuation, Grade ≥ 3 infections, and neuropathy. Novel agent‐based regimens produced better efficacy and lower toxicity than traditional chemotherapy in newly diagnosed older adults with cHL. Among novel agents, nivolumab‐based regimens had more favorable efficacy and tolerability than BV‐based regimens, though these comparisons are indirect and may reflect differences in study design and patient selection.
- 14 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1079.e1-1079.e3
Prevalence of Clinically Significant Viral and Bacterial Enteric Pathogens Among Indian Hematopoietic Stem Cell Transplant Recipients and Allogeneic Donors
- 14 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1079.e1-1079.e3
Prevalence of Clinically Significant Viral and Bacterial Enteric Pathogens Among Indian Hematopoietic Stem Cell Transplant Recipients and Allogeneic Donors
- 26 February 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , e657-e660
Reversing Transplant Ineligibility With Teclistamab in Ultra–High-Risk Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- 26 February 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , e657-e660
Reversing Transplant Ineligibility With Teclistamab in Ultra–High-Risk Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- 18 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (5) , 1854-1857
Non‐ ICANS neurological toxicities associated with BCMA‐ directed CAR T‐cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis
- 18 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (5) , 1854-1857
Non‐ ICANS neurological toxicities associated with BCMA‐ directed CAR T‐cell therapy in patients with plasma cell dyscrasia: A systematic review and pooled analysis
- 12 August 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (5) , e14123
Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients
Background: Infections are a significant cause of morbidity and mortality after autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients. There has been a rapid advancement and evolution in MM treatment landscape in the last decade. There is limited information on post‐AHCT infectious complications among MM patients with or without levofloxacin prophylaxis from developing countries.Materials and methods: We performed a retrospective study to explore the incidence, pattern, and clinical outcome of infections following AHCT in MM patients from 2010 to 2019 at our center. Patient‐specific, disease‐specific, and transplant‐specific details were retrieved from the case files. The characteristics of infectious complications (site, intensity, organism, treatment, and outcomes) were analyzed. All patients who underwent transplantation from 2010 to 2016 received levofloxacin antibiotic prophylaxis. Common terminology criteria for adverse events (CTCAE) criteria (v5.0) were used for the grading of infections and regimen‐related toxicity. International Myeloma Working Group updated criteria were used for the assessment of disease response before transplant and at day +100.Results: Ninety‐five consecutive patients with newly diagnosed multiple myeloma (NDMM) (n = 85), RRMM (n = 7), plasma cell leukemia (n = 2), and Polyneuropathy, Orgaomegaly, Endocrinopathy, Monoclonal gammopathy, skin abnormalities (POEMS) syndrome (n = 1) underwent AHCT during the study period. Their median age was 55 years (range 33–68); 55.8% were males. Immunoglobulin IgG kappa was the most common monoclonal protein (32.6%), International Staging System stage III disease was present in 45.3%, and 84.2% of patients achieved more than very good partial response before AHCT. The median time from diagnosis to AHCT was 10 months (range 4–144). Eighty‐nine patients (93.7%) developed fever after AHCT. Fever of unknown focus, microbiologically confirmed infections, and clinically suspected infections were found in 50.5%, 37.9%, and 5.3% of patients, respectively. Clostridiodes difficile‐associated diarrhea was observed in eight patients (8.4%). Neutrophil and platelet engraftment occurred after a median of 11 days (range 9–14) and 12 days (range 9–23), respectively. The median duration of hospital stay was 16 days (range 9–29). Only two patients (2.1%) required readmission for infections within 100 days of AHCT. Transplant‐related mortality (TRM) in the study population was 4.2% (n = 4). The levofloxacin prophylaxis group (n = 32, 33.7%) had earlier neutrophil engraftment (day +10 vs. day +11) and platelet engraftment (day +11 vs. day +12), but time to fever onset, duration of fever, hospital stay, TRM, and day +100 readmission rates were not significantly different from those of patients without levofloxacin prophylaxis. There was no significant difference in the spectrum of infections between patients with and without levofloxacin prophylaxis. The overall survival and progression‐free survival of the study population at 5 years were 72.7% and 64.8%, respectively.Conclusion: This study shows that the incidence of infections and TRM are higher in MM patients from lower‐middle income countries after AHCT than in those from developed countries. The majority of such patients lack clinical localization and microbiological proof of infection. There was no significant difference in the spectrum of infections and their outcomes in patients with and without levofloxacin prophylaxis. image
- 12 August 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (5) , e14123
Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients
Background: Infections are a significant cause of morbidity and mortality after autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) patients. There has been a rapid advancement and evolution in MM treatment landscape in the last decade. There is limited information on post‐AHCT infectious complications among MM patients with or without levofloxacin prophylaxis from developing countries.Materials and methods: We performed a retrospective study to explore the incidence, pattern, and clinical outcome of infections following AHCT in MM patients from 2010 to 2019 at our center. Patient‐specific, disease‐specific, and transplant‐specific details were retrieved from the case files. The characteristics of infectious complications (site, intensity, organism, treatment, and outcomes) were analyzed. All patients who underwent transplantation from 2010 to 2016 received levofloxacin antibiotic prophylaxis. Common terminology criteria for adverse events (CTCAE) criteria (v5.0) were used for the grading of infections and regimen‐related toxicity. International Myeloma Working Group updated criteria were used for the assessment of disease response before transplant and at day +100.Results: Ninety‐five consecutive patients with newly diagnosed multiple myeloma (NDMM) (n = 85), RRMM (n = 7), plasma cell leukemia (n = 2), and Polyneuropathy, Orgaomegaly, Endocrinopathy, Monoclonal gammopathy, skin abnormalities (POEMS) syndrome (n = 1) underwent AHCT during the study period. Their median age was 55 years (range 33–68); 55.8% were males. Immunoglobulin IgG kappa was the most common monoclonal protein (32.6%), International Staging System stage III disease was present in 45.3%, and 84.2% of patients achieved more than very good partial response before AHCT. The median time from diagnosis to AHCT was 10 months (range 4–144). Eighty‐nine patients (93.7%) developed fever after AHCT. Fever of unknown focus, microbiologically confirmed infections, and clinically suspected infections were found in 50.5%, 37.9%, and 5.3% of patients, respectively. Clostridiodes difficile‐associated diarrhea was observed in eight patients (8.4%). Neutrophil and platelet engraftment occurred after a median of 11 days (range 9–14) and 12 days (range 9–23), respectively. The median duration of hospital stay was 16 days (range 9–29). Only two patients (2.1%) required readmission for infections within 100 days of AHCT. Transplant‐related mortality (TRM) in the study population was 4.2% (n = 4). The levofloxacin prophylaxis group (n = 32, 33.7%) had earlier neutrophil engraftment (day +10 vs. day +11) and platelet engraftment (day +11 vs. day +12), but time to fever onset, duration of fever, hospital stay, TRM, and day +100 readmission rates were not significantly different from those of patients without levofloxacin prophylaxis. There was no significant difference in the spectrum of infections between patients with and without levofloxacin prophylaxis. The overall survival and progression‐free survival of the study population at 5 years were 72.7% and 64.8%, respectively.Conclusion: This study shows that the incidence of infections and TRM are higher in MM patients from lower‐middle income countries after AHCT than in those from developed countries. The majority of such patients lack clinical localization and microbiological proof of infection. There was no significant difference in the spectrum of infections and their outcomes in patients with and without levofloxacin prophylaxis. image
- 2 August 2023
- Published by Elsevier in Leukemia Research
- Vol. 133, 107367
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies
- 2 August 2023
- Published by Elsevier in Leukemia Research
- Vol. 133, 107367
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies
- Open Access
- 23 May 2023
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 16 (4) , 426-431
Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review
Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.
- 23 May 2023
- Published by Wolters Kluwer Health in Hematology/Oncology and Stem Cell Therapy
- Vol. 16 (4) , 426-431
Open AccessCarfilzomib-induced Thrombotic Microangiopathy: A Case Based Review
Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.